Global Genome Editing Market Report

Genome Editing Market Size and Forecast 2024 to 2032

The global Genome Editing Market size is projected to be worth around USD 22.68 Billion by 2032 from USD 6.76 Billion in 2023 with a CAGR of 14.14% under the study period 2024-2032.

• The genome editing market is experiencing robust expansion, driven by advancements in therapeutic applications, particularly for treating genetic disorders. This growth is underpinned by investments in research initiatives, such as those from the National Institutes of Health, which continue to fund ground-breaking genome editing studies. Moreover, agricultural biotechnology companies are leveraging gene editing to develop crops with improved resistance to diseases, pests, and environmental stress. Global demand for genetically modified crops, especially in North America and Asia-Pacific regions, further underscores the sector's potential. However, ethical considerations and regulatory landscapes remain key challenges, shaping the adoption and trajectory of genome editing technologies.
• Genome editing, also known as gene editing, is a transformative biotechnological approach that enables precise alterations in the DNA sequence of living organisms. This field is witnessing exponential growth due to its potential applications in medicine, agriculture, and industrial biotechnology. Technologies like CRISPR-Cas9, TALENs, and ZFNs have revolutionized the ease and affordability of editing genetic material, sparking a wave of innovation across industries.

Top 3 Trends to Watch in the Genome Editing Market

• Expansion of CRISPR-Based Therapeutics: The rapid adoption of CRISPR-Cas9 technology is reshaping the landscape of gene therapies, with its application now extending beyond rare genetic disorders to more common diseases like cancer and diabetes. CRISPR-based therapeutics are gaining traction as companies such as Intellia Therapeutics and CRISPR Therapeutics achieve promising clinical trial results. For instance, Intellia reported significant advancements in vivo editing for hereditary conditions like transthyretin amyloidosis in 2023. The global CRISPR market is anticipated to grow, spurred by rising demand for effective, one-time treatments.
• Increasing Agricultural Applications: Gene editing is becoming an integral part of agricultural biotechnology, enabling the development of high-yield, climate-resilient crops. Tools like CRISPR are being deployed to produce drought-resistant wheat and pest-resistant rice, addressing global food security challenges. According to insights from the International Service for the Acquisition of Agri-biotech Applications, gene-edited crops will form a significant share of the $21 billion agricultural biotechnology market by 2027. Multinational companies, including Bayer and Corteva Agriscience, are at the forefront of integrating genome editing into sustainable farming solutions.
• Regulatory and Ethical Frameworks Shaping Adoption: While technological advancements are driving genome editing forward, the regulatory and ethical landscape is becoming a pivotal determinant of its adoption. Countries like the U.S. and Japan are leading efforts to standardize policies, with the Food and Drug Administration approving clinical trials for CRISPR-based therapies in 2023. However, stricter regulations under the precautionary principle have slowed agricultural applications in regions like the European Union. Ethical concerns about off-target effects and germline editing continue to fuel debates, underscoring the need for transparent, global governance frameworks. These dynamics are influencing market growth and investment trends.

Demand and Supply Trends in the Genome Editing Market

• Surging Demand for Personalized Medicine: The increasing focus on personalized medicine drives demand in the genome editing market. Patients and healthcare providers are seeking therapies tailored to individual genetic profiles, particularly for conditions such as cancer, cystic fibrosis, and rare genetic diseases. Genome editing tools enable the development of targeted treatments, reduce side effects, and improve efficacy. According to data from the Global Personalized Medicine Coalition, the market for personalized therapies is projected to grow at a CAGR of 11%, further propelling demand for gene-editing technologies. This trend is particularly prominent in North America and Europe, where advancements in precision medicine are shaping treatment paradigms.
• Supply Chain Expansion in Agricultural Genomics: The supply side of genome editing is significantly influenced by agricultural applications, where demand for resilient crops is high. Biotechnology firms are scaling up the production of gene-editing kits and reagents, supported by advancements in CRISPR and TALEN technologies. As per the International Seed Federation, global investments in agricultural biotechnology are increasing by approximately 10% annually, with companies like Syngenta and Monsanto expanding their supply chains to meet the needs of large-scale farming enterprises. This robust supply trend is particularly evident in developing regions, where genetically modified crops are increasingly embraced to counteract climate-related challenges.

Top Investment Pockets in the Genome Editing Market

• In Vivo Therapeutics: In vivo applications are emerging as a top investment area for addressing hereditary and chronic diseases. Companies are channeling funds into developing genome editing tools that directly modify genes within the human body. For instance, Editas Medicine recently raised substantial capital to advance clinical trials for in vivo therapies targeting eye disorders like Leber congenital amaurosis. The National Institutes of Health estimates investments in in vivo gene therapies are growing at over 12% annually, driven by the potential to revolutionize treatment for untreatable conditions.
• Cell and Gene Therapy Manufacturing: Investment in cell and gene therapy manufacturing infrastructure is another prominent pocket. With the increasing clinical success of genome-edited therapies, there is a pressing need for scalable production facilities. Firms like Thermo Fisher Scientific and Catalent spearhead initiatives to build specialized manufacturing units. According to the Alliance for Regenerative Medicine, global investment in cell and gene therapy manufacturing surpassed $20 billion in 2023, a figure expected to rise as demand for commercial-scale production grows.

Market Dynamics

Top 3 Drivers of the Genome Editing Market

• Advancements in Gene-Editing Technologies: Breakthroughs in tools like CRISPR-Cas9 and base editing are significantly driving the genome editing market. These technologies have drastically improved genetic modifications' precision, efficiency, and affordability. A study published by the Broad Institute highlighted that CRISPR's error rates have declined by over 50% in recent years due to improved algorithms and delivery mechanisms. This progress has spurred its adoption in therapeutic, agricultural, and industrial applications, positioning the market for continued growth. The global CRISPR-Cas9 market alone is expected to flourish, with growing interest from pharmaceutical and biotech companies.
• Growing Prevalence of Genetic Disorders: The increasing incidence of genetic disorders is a major market driver, creating a pressing need for effective genome-editing solutions. Disorders like sickle cell anemia and Duchenne muscular dystrophy are prime targets for innovative gene therapies. According to the World Health Organization, genetic disorders affect approximately 10% of the global population, underscoring the market potential for genome-editing interventions. This demand is further fuelled by healthcare initiatives in developed and developing nations, leading to a surge in clinical trials and regulatory approvals.
• Government and Private Funding Initiatives: Significant investments from government bodies and private entities are catalyzing the development of genome editing technologies. Research grants from organizations like the European Commission and the National Institutes of Health have increased by over 15% in the past five years. Similarly, venture capital investments in gene editing startups surpassed $3 billion in 2023, as reported by PitchBook. These funding initiatives are accelerating innovation, particularly in North America and Asia-Pacific regions, where regulatory environments are more conducive to biotechnological advancements.

Top 3 Opportunities of the Genome Editing Market

• Development of Precision Oncology Therapies: The rising prevalence of cancer worldwide presents a significant opportunity for the genome editing market, particularly in developing precision oncology therapies. Genome editing tools like CRISPR and TALENs are used to identify and target mutations that drive cancer progression, enabling personalized treatments. According to the World Cancer Research Fund, there were over 19 million new cancer cases globally in 2023, underscoring the urgent need for innovative therapies. Companies such as Novartis are pioneering gene-editing approaches to create CAR-T cell therapies, which modify a patient’s immune cells to attack tumors. The oncology sector represents a lucrative market, projected to account for nearly 30% of gene therapy-related revenues by 2030.
• Expansion into Non-Human Applications: Genome editing technologies are finding growing applications beyond humans, including livestock and aquaculture. These technologies are being used to improve agricultural practices' productivity, health, and sustainability. For instance, gene-edited livestock is engineered to resist diseases like African swine fever, which costs the global pig industry billions annually. According to the Food and Agriculture Organization, investments in aquaculture and livestock genome editing are growing at a CAGR of over 10%, reflecting increasing interest in sustainable food systems. Companies like Genus PLC are capitalizing on this opportunity by developing genetically resilient animals.
• Integration with Artificial Intelligence: Integrating artificial intelligence (AI) with genome editing tools opens new frontiers in predictive analytics and editing precision. AI algorithms are accelerating the identification of gene targets, reducing the time required for research and development. According to insights from the MIT Technology Review, the use of AI in genome editing is expected to increase R&D efficiency by up to 40% by 2030. Leading players such as Inscripta and Synthego are investing in AI-powered platforms to optimize gene-editing workflows. This synergy is anticipated to drive significant advancements in therapeutic and industrial applications.

Top 3 Restraints of the Genome Editing Market

• Ethical and Social Concerns: Ethical debates surrounding genome editing, particularly germline modifications, significantly restrain market growth. Public concerns about potential misuse, such as "designer babies," and unintended ecological consequences in agriculture have heightened scrutiny. According to a Pew Research Center study in 2023, nearly 65% of Americans expressed concerns about the ethical implications of gene editing. These issues have led to stringent regulations in several regions, including Europe, where genetic modifications are heavily restricted under precautionary principles, hampering the pace of innovation.
• High Costs of Genome Editing Therapies: The high costs associated with genome editing technologies and treatments limit their accessibility, particularly in low- and middle-income countries. For instance, CRISPR-based therapies for conditions like sickle cell anemia can cost upwards of $1 million per patient, as the Institute for Clinical and Economic Review reported in 2023. The significant financial burden on healthcare systems and patients restricts market penetration. Efforts to reduce costs through scalable manufacturing and improved delivery systems are underway but remain insufficient to address this challenge.
• Regulatory Challenges and Regional Disparities: Regulatory inconsistencies across countries impede the commercialization of genome editing products. While the U.S. and China have relatively supportive regulatory environments, stringent approval processes in regions like the European Union delay product launches. The European Court of Justice’s classification of genome-edited crops as genetically modified organisms in 2023 exemplifies such barriers. According to the Organisation for Economic Co-operation and Development, these disparities result in prolonged development timelines and increased costs, creating significant hurdles for market players.

Top 3 Challenges of the Genome Editing Market

• Off-Target Effects and Technical Limitations: Despite advancements, the risk of off-target mutations remains a significant challenge in genome editing. Off-target effects occur when genome-editing tools inadvertently modify unintended regions of the DNA, potentially leading to harmful consequences. According to a 2023 report by Nature Biotechnology, off-target mutation rates for CRISPR systems range between 0.1% and 2%, raising concerns about the safety and efficacy of therapies. Researchers are actively developing more precise techniques, such as base editing, to address this challenge, but their widespread adoption is still nascent.
• Limited Expertise and Skilled Workforce: Genome editing requires a highly skilled workforce, but there is a notable shortage of trained professionals in this domain. The demand for expertise in molecular biology, computational biology, and bioinformatics far outpaces the supply. According to the National Science Board's 2023 Science and Engineering Indicators report, the global demand for life sciences professionals is expected to grow by 25% by 2030. This skills gap hampers R&D efforts and slows technological progress, particularly in emerging markets with limited educational infrastructure.
• Intellectual Property Disputes: Intellectual property disputes frequently disrupt the genome editing market, particularly regarding foundational technologies like CRISPR. Legal battles between institutions such as the University of California, Berkeley, and the Broad Institute have prolonged commercialization timelines and created uncertainty for companies relying on patented technologies. In 2023, these disputes delayed the development of certain therapeutic applications, impacting market growth. Resolving these conflicts and establishing clearer patent frameworks will be essential for fostering innovation and market expansion.

Segmentation Insights

Genome Editing Market Analysis, By Technology

• CRISPR/Cas9 dominates the genome editing market, accounting for approximately 58.7% of the global market share in 2023. Its unparalleled precision, cost-effectiveness, and versatility have made it the preferred choice for genetic modifications across multiple sectors, including therapeutics and agriculture. CRISPR’s ability to edit single genes with minimal off-target effects has been pivotal in treating genetic disorders such as sickle cell anaemia and beta-thalassemia. The scalability of CRISPR has also led to its widespread adoption in R&D, particularly in pharmaceutical companies. In 2023, over 70% of clinical trials involving genome editing technologies used CRISPR, highlighting its importance in the market.
• Base editing is the fastest-growing technology, with a CAGR of 31.5% projected during the forecast period, according to a report by Nature Biotechnology. Unlike CRISPR, which cuts DNA, base editing precisely alters a single nucleotide without inducing double-strand breaks, minimizing risks. This makes it particularly valuable for correcting point mutations responsible for genetic diseases such as progeria. Companies like Beam Therapeutics are leading advancements in base editing, which is expected to expand rapidly due to its therapeutic potential and growing investment in R&D.

Genome Editing Market Analysis By Delivery Method

• Ex-vivo delivery is the leading segment, capturing 57.3% of the market share 2023. This method involves editing cells outside the patient’s body before reintroducing them, providing greater control and minimizing off-target effects. Ex-vivo approaches are widely used in CAR-T cell therapies for cancer treatment, where immune cells are modified to target tumors. The precision and safety of ex-vivo methods have made them the gold standard in therapeutic applications, particularly for complex conditions such as hematological malignancies.
• In-vivo delivery is the fastest-growing segment, with a CAGR of 27.6% during the forecast period. This method directly edits genes within the patient’s body, offering transformative potential for treating systemic genetic disorders. Advances in delivery vectors, such as lipid nanoparticles and adeno-associated viruses, enhance in-vivo precision and efficiency. Recent successes in clinical trials for in-vivo therapies targeting Duchenne muscular dystrophy and retinal diseases underscore its growing importance.

Genome Editing Market Analysis, By Application

• Therapy development leads the genome editing market, accounting for 54.8% of the market share in 2023. Genome editing tools are widely used to develop genetic disorders, infectious diseases, and cancer treatments. Advances in CRISPR and other technologies have accelerated the pipeline for gene therapies, with several FDA-approved products now available. The segment's dominance is driven by the high demand for novel therapies, supported by increased funding in biopharmaceutical research.
• The diagnostics segment is growing at a rapid CAGR of 28.7% during the forecast period. Genome editing tools are being leveraged for early disease detection, enabling precision diagnostics at the molecular level. For instance, CRISPR-based diagnostics are being developed for infectious diseases like COVID-19 and tuberculosis. The ability to provide real-time, highly specific results drives adoption in clinical and point-of-care settings.

Genome Editing Market Analysis, By End-Use

• Biotechnology and pharmaceutical companies hold the largest share, representing 64.6% of the market in 2023. These companies are the primary drivers of R&D for genome editing tools, leveraging them to develop ground-breaking therapeutics and vaccines. Strategic collaborations, such as those between CRISPR Therapeutics and Vertex Pharmaceuticals, highlight the dominance of this segment, which continues to receive substantial investments.
• CROs are the fastest-growing end-use segment, with a projected CAGR of 23.8% during the forecast period. Outsourcing genome editing projects to specialized CROs is increasing, driven by cost efficiencies and access to advanced expertise. CROs support clinical trials and regulatory compliance, particularly for small and medium-sized biotech firms.

Genome Editing Market Analysis, By Mode

• In-house genome editing operations dominate, accounting for 67.4% of the market in 2023. Large pharmaceutical and biotechnology firms prefer in-house capabilities to maintain intellectual property control and ensure quality. This approach is prevalent in companies like Pfizer, which has invested heavily in internal R&D for gene editing.
• The contract mode is growing at a remarkable CAGR of 28.4% during the forecast period. Outsourcing genome editing projects allows companies to reduce costs and accelerate timelines. Contract operations are gaining popularity, especially among startups and smaller firms lacking extensive infrastructure. Specialized providers like Lonza and Catalent are driving growth in this segment by offering tailored genome editing services.

Genome Editing Market Regional Insights

• North America dominates the genome editing market, accounting for approximately 44.3% of global revenue in 2023, as the National Institutes of Health reported. The region's leadership is attributed to robust investments in biotechnology, advanced healthcare infrastructure, and a strong focus on research and development. The U.S. is the primary driver of this growth, hosting major companies like CRISPR Therapeutics and Intellia Therapeutics. Over 60% of ongoing clinical trials involving genome editing are conducted in North America, reflecting its innovation-driven approach. Moreover, supportive regulatory frameworks, such as the FDA’s expedited approval pathways for gene therapies, bolster market growth. North America's genome editing market is projected to grow at a CAGR of 17.5% during the forecast period, driven by increased adoption in precision medicine and agricultural biotechnology.
• According to data from the Asia-Pacific Biotechnology Forum, Asia-Pacific is the fastest-growing region in the genome editing market, with a projected CAGR of 24.6% during the forecast period. Rising investments in R&D, government initiatives, and the increasing prevalence of genetic disorders fuel this rapid growth. China and Japan are leading countries in the region, with significant advancements in agricultural and medical genome editing applications. For instance, China has heavily invested in CRISPR research to enhance crop yields and disease resistance. Additionally, the region's cost-effective manufacturing capabilities and expanding biotechnology workforce position it as a global hub for genome editing innovation. Asia-Pacific is expected to witness sustained growth due to its strategic focus on technological advancements and collaborations with international players.

Genome Editing Market Competitive Overview

The genome editing market is marked by intense competition, driven by rapid technological advancements and significant R&D investments. Key players, including CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, are leading the innovation curve, focusing on developing cutting-edge therapies for genetic disorders. Partnerships and collaborations are vital strategies for market players to expand their portfolios. For instance, AstraZeneca and Horizon Discovery have formed alliances to accelerate drug discovery applications using genome editing. Merck KGaA has maintained its leadership in providing genome editing tools for research and therapeutic development, with a 20% market share in the tools segment as of 2023. Emerging players like Caribou Biosciences are gaining traction by focusing on niche applications such as agricultural genome editing. With global funding for genome editing exceeding $15 billion in 2023 (as per the National Genome Research Institute), the competitive landscape remains dynamic, driven by innovation, strategic alliances, and expanding applications across diverse industries.

Top 3 Players in the Genome Editing Market

• CRISPR Therapeutics: CRISPR Therapeutics is a leader in the genome editing market, renowned for its pioneering work in CRISPR-Cas9 technology. The company focuses on developing transformative therapies for hemoglobinopathies and other genetic disorders. In 2023, its ex-vivo treatment for beta-thalassemia and sickle cell anemia received regulatory approvals, propelling its market position. With revenues exceeding $450 million in 2023, CRISPR Therapeutics is expanding its therapeutic pipeline through strategic collaborations, such as its partnership with Vertex Pharmaceuticals, which has enabled significant advancements in clinical trials.
• Intellia Therapeutics: Intellia Therapeutics is at the forefront of in vivo genome editing, leveraging CRISPR-Cas9 for systemic treatments. The company achieved a milestone in 2023 with promising Phase I results for transthyretin amyloidosis therapy, highlighting its potential to revolutionize treatment for hereditary diseases. Intellia has a robust R&D strategy, allocating over 40% of its annual budget to innovation. Its partnership with Regeneron Pharmaceuticals underpins its efforts to expand into diverse therapeutic areas, including cancer immunotherapy.
• Editas Medicine: Editas Medicine specializes in editing therapies targeting rare genetic disorders, focusing on ex-vivo and in vivo approaches. In 2023, Editas reported strong progress in treating retinal diseases, with its EDIT-101 therapy demonstrating significant clinical success. The company’s partnership with Allergan has amplified its reach in ophthalmology. With a robust intellectual property portfolio encompassing multiple CRISPR technologies, Editas is well-positioned for future growth.

Top 3 Strategies Followed by Major Players

• Collaborative Partnerships: Leading companies leverage collaborations to enhance R&D capabilities and accelerate commercialization. For instance, CRISPR Therapeutics' partnership with Vertex Pharmaceuticals has resulted in groundbreaking advancements in sickle cell and beta-thalassemia therapies, projected to generate over $1 billion in annual sales by 2025. Such partnerships enable shared resources and risk mitigation, driving the rapid development of innovative therapies.
• Diversification of Applications: Key players are diversifying their applications beyond therapeutics to include agriculture and industrial biotechnology. Merck KGaA, for instance, has developed genome editing tools for creating disease-resistant crops, addressing global food security challenges. Diversification broadens market scope and mitigates dependency on the highly regulated pharmaceutical sector, ensuring steady revenue streams.
• Focus on Advanced Technologies: Investing in next-generation genome editing tools, such as base editing and prime editing, is a core strategy for market leaders. Intellia Therapeutics and Beam Therapeutics are spearheading base editing efforts to enhance precision and safety in gene modifications. This approach allows companies to capture niche markets and position themselves at the forefront of innovation.

A list of Key Companies Operating in the Genome Editing Market Include

1. Merck KGaA
2. Cibus Inc.
3. Recombinetics
4. Sangamo Therapeutics
5. Editas Medicine
6. Precision Biosciences
7. CRISPR Therapeutics
8. Intellia Therapeutics Inc.
9. Caribou Biosciences Inc.
10. Cellectis S.A.
11. AstraZeneca
12. Takara Bio Inc.
13. Horizon Discovery Ltd. (Revvity Inn Inc.)

Recent Developments in the Genome Editing Market

• Development of Prime Editing Technology: Prime editing, an innovative approach beyond CRISPR's capabilities, emerged as a revolutionary tool in 2024. It enables precise and versatile DNA modifications, reducing off-target effects and double-strand breaks. Researchers at the Broad Institute have optimized prime editing to correct point mutations responsible for genetic disorders such as Tay-Sachs disease. This advancement has accelerated therapeutic applications, with companies like Beam Therapeutics investing $200 million in R&D for prime editing applications.
• Lipid Nanoparticles for Enhanced Delivery: Due to their biocompatibility and efficiency, lipid nanoparticles (LNPs) are becoming a preferred delivery system for in vivo genome editing. In 2024, researchers at Takara Bio Inc. demonstrated a 40% increase in gene-editing success rates using LNPs compared to viral vectors. This innovation has significantly improved the delivery of CRISPR-Cas9 therapies, particularly for treating systemic diseases like cystic fibrosis.
• CRISPR-Based Diagnostics Innovations: CRISPR diagnostics have made strides with the introduction of SHERLOCK and DETECTR platforms for detecting infectious diseases. In 2024, Merck KGaA launched a CRISPR-based diagnostic tool capable of identifying multiple pathogens within an hour, with an accuracy rate of 95%. This advancement is particularly beneficial for point-of-care testing in remote areas.
• Synthetic Gene Editors for High-Precision Applications: Synthetic gene editors have gained traction for modifying larger genomes with minimal errors. In 2024, Precision Biosciences announced the development of ARCUS synthetic editors, which provide superior targeting capabilities for complex genetic disorders. The company reported a 30% reduction in off-target effects compared to traditional CRISPR methods.

Recent Happenings in the Genome Editing Market

• November 2024: Caribou Biosciences announced a collaboration with Bayer to develop CRISPR-based gene editing therapies for the treatment of various diseases. The collaboration will focus on developing therapies for diseases with high unmet medical need, such as cancer and genetic disorders.
• April 2024: CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the Phase 1/2 clinical trial of CTX001, a CRISPR-based therapy for sickle cell disease and transfusion-dependent beta-thalassemia. The data demonstrated significant improvements in hemoglobin levels and reduced transfusion dependence in patients.
• March 2024: Intellia Therapeutics initiated a Phase 1/2 clinical trial of NTLA-2001, a CRISPR-based therapy for hereditary angioedema (HAE). The trial aims to evaluate its safety and efficacy in reducing HAE attacks.
• February 2024: Editas Medicine announced positive interim data from the Phase 1/2 clinical trial of EDIT-101, a CRISPR-based Leber congenital amaurosis 10 (LCA10) therapy. The data showed improvements in visual function in treated patients.
• January 2024: Precision Biosciences initiated a Phase 1/2 clinical trial of PBCAR-0191, an allogeneic CAR-T cell therapy engineered using its proprietary ARCUS genome editing platform. The trial aims to evaluate the safety and efficacy of PBCAR-0191 in patients with relapsed or refractory multiple myeloma.
• December 2023: Sangamo Therapeutics announced positive interim data from the Phase 1/2 clinical trial of ST-920, a gene therapy for hemophilia A. The data showed sustained increases in factor VIII levels and reduced bleeding episodes in treated patients.
• November 2023: Cellectis S.A. announced positive interim data from the Phase 1/2 clinical trial of UCART19, a CAR-T cell therapy engineered using its proprietary TALEN gene editing platform. The data showed encouraging results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
• October 2023: Caribou Biosciences Inc. announced a collaboration with Vertex Pharmaceuticals to develop CRISPR-based therapies for various diseases, including cystic fibrosis. The collaboration aims to leverage both companies' strengths to accelerate the development of innovative treatments.

Global Genome Editing Market Report: Scope

List of Segments Covered

This section of the Genome Editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

• CRISPR/Cas9
• TALENs/MegaTALs
• Prime Editing
• Base Editing
• Cpf1 (CRISPR from Prevotella and Francisella 1)
• CasX and CasY
• ZFN
• Meganucleases
• Oligonucleotide-Directed Mutagenesis (ODM)
• Synthetic Gene Editors
• Transcription Activator-Like Effector Base Editors (TALE-BE)
• Other

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
• Clinical Applications (Diagnostics, Therapy Development)
• Others

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

By Mode

• Contract
• In-House